Penumbra (NYSE:PEN – Get Free Report)‘s stock had its “hold” rating reissued by stock analysts at Canaccord Genuity Group in a note issued to investors on Tuesday, Benzinga reports. They currently have a $374.00 target price on the stock. Canaccord Genuity Group‘s target price suggests a potential upside of 16.75% from the company’s previous close.
Other equities analysts have also recently issued research reports about the stock. Zacks Research upgraded shares of Penumbra from a “strong sell” rating to a “hold” rating in a research note on Monday, August 24th. Weiss Ratings raised shares of Penumbra from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, October 30th. Three equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $367.07.
View Our Latest Research Report on Penumbra
Penumbra Stock Performance
Penumbra (NYSE:PEN – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $1.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.13). The firm had revenue of $410.15 million during the quarter, compared to analysts’ expectations of $401.41 million. Penumbra had a return on equity of 10.39% and a net margin of 10.06%. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.97 earnings per share. As a group, equities analysts anticipate that Penumbra will post 4.96 earnings per share for the current year.
Institutional Investors Weigh In On Penumbra
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Aquatic Capital Management LLC purchased a new stake in shares of Penumbra in the third quarter worth $5,851,000. WCG Wealth Advisors LLC bought a new stake in shares of Penumbra during the 3rd quarter valued at $214,000. Credit Industriel ET Commercial raised its position in shares of Penumbra by 9.6% during the 3rd quarter. Credit Industriel ET Commercial now owns 57,052 shares of the company’s stock valued at $18,162,000 after purchasing an additional 4,974 shares during the period. Empowered Funds LLC purchased a new position in shares of Penumbra during the 3rd quarter valued at $418,000. Finally, Steward Partners Investment Advisory LLC lifted its stake in shares of Penumbra by 47.7% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 2,499 shares of the company’s stock valued at $796,000 after buying an additional 807 shares in the last quarter. Institutional investors own 88.88% of the company’s stock.
About Penumbra
Penumbra, Inc. is a medical technology company that develops and markets devices for treating vascular conditions. Its products are used in neurovascular procedures, including the treatment of ischemic stroke and aneurysms, and in peripheral vascular procedures involving conditions such as pulmonary embolism and deep vein thrombosis. The company’s offerings include aspiration and mechanical thrombectomy systems, embolization coils, and related catheter-based devices. Penumbra was founded in 2004 and is headquartered in Alameda, California.
Further Reading
- Five stocks we like better than Penumbra
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.
